Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BAROnova Inc.

Latest From Ethypharm SA

China Investment Roundup: Strategic Overseas Moves Target Product Acquisitions

R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.

China Financing

Luye Looks To Horizons Beyond Pharma, China

Dianbo Liu, chairman of the Hong Kong listed Luye Group, talks about the company’s ambitious plans to become a global top 100 pharmaceutical company through innovation, acquisitions and overseas expansion, and to broaden its activities well beyond selling medicines to meet changing patient needs and industry pressures.

Companies China

Speculation Mounts Over Chinese Interest In Ethypharm

French firm Ethypharm’s portfolio in CNS and pain management is apparently attracting interest from Chinese and other pharma groups in a potential strategic acquisition, with Luye Pharma and Mundipharma emerging as possible bidders given their interest in M&A as a route to business expansion.

BioPharmaceutical Asia Pacific

TCMs Gain Further U.S. Ground As New Phase III Trial Starts

A Hangzhou-based developer of traditional Chinese medicines (TCMs) has been given the green light by the U.S. Food and Drug Administration to conduct Phase III trials with an injectable TCM-based anticancer drug, which could become the first of its type to enter the U.S. market. The company is also seeking strategic partnerships with big pharmas to advance the trials and for future global development.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BAROnova Inc.
  • Senior Management
  • David S Thrower, Pres. & CEO
    Kobi Iki, VP, R&D
  • Contact Info
  • BAROnova Inc.
    Phone: (805) 681-7000
    281 Magnolia Ave., Ste. 300
    Goleta, CA 93117